SCHEMBL17513342

SCHEMBL17513342

O=C(O)CC(=O)NCc1cc(Cl)cc(Cl)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.59
P2RX7 Q99572 1/20 0.49
GAA P10253 1/20 0.46
POLB P06746 1/20 0.42
KMT2A Q03164 3/20 0.42
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
MEN1 O00255 2/20 0.41
FABP4 P15090 2/20 0.41
METAP2 P50579 1/20 0.41
ALDH1A1 P00352 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
TPSAB1 Q15661 1/20 0.40
HPGD P15428 1/20 0.40
ACLY P53396 1/20 0.40
WDR5 P61964 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
HSD17B2 P37059 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17513378 0.85 TACR1 (0.56) TACR1P2RX7GAAKMT2AMEN1
SCHEMBL31248396 0.82 TACR1 (0.57) TACR1P2RX7GAAKMT2AERCC1
SCHEMBL11121464 0.82 TACR1 (0.56) TACR1P2RX7KMT2AMEN1FABP4
SCHEMBL8310876 0.81 TACR1 (0.55) TACR1P2RX7KMT2AERCC1ERCC4
SCHEMBL7932262 0.81 TACR1 (0.55) TACR1P2RX7GAAKMT2AERCC1
SCHEMBL5016282 0.77 HTT (0.50) POLBKMT2AMETAP2ALDH1A1RAB9A
SCHEMBL23135792 0.77 P2RX7 (0.52) TACR1P2RX7GAAPOLBKMT2A
SCHEMBL19377955 0.76 MEN1 (0.49) TACR1P2RX7GAAKMT2AMEN1
1,3,5-Trichlorobenzene SCHEMBL29135209 0.76 TPMT (0.55) POLBKMT2AMEN1FABP4ALDH1A1
SCHEMBL626342 0.76 CYP2C9 (0.66) TACR1P2RX7POLBKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016029146-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON (US) 2016-02-25 WO claimed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase UNIVERSITY OF WASHINGTON (US) 2021-02-09 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE UNIVERSITY OF WASHINGTON 2017-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170275279-A1 SPECIFIC INHIBITORS OF METHIONYL-TRNA SYNTHETASE AARS1, MTR, GARS1 TACR1 4007/4885P2RX7 4341/4885GAA 671/4885
US-10913736-B2 Specific inhibitors of methionyl-tRNA synthetase AARS1, MTR, GARS1 TACR1 4007/4885P2RX7 4341/4885GAA 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.